Premorbid vulnerability and disease severity impact on Long-COVID cognitive impairment.
COVID-19
Cognitive functions
Long-COVID
Neurology
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
05
11
2021
accepted:
21
11
2021
pubmed:
12
1
2022
medline:
1
2
2022
entrez:
11
1
2022
Statut:
ppublish
Résumé
Cognitive deficits have been increasingly reported as possible long-term manifestations after SARS-CoV-2 infection. In this study we aimed at evaluating the factors associated with cognitive deficits 6 months after hospitalization for Coronavirus Disease 2019 (COVID-19). One hundred and six patients, discharged from a pneumology COVID-19 unit between March 1 and May 30 2020, accepted to be evaluated at 6 months according to an extensive neurological protocol, including the Montreal Cognitive Assessment (MoCA). Abnormal MoCA scores at 6 months follow-up were associated with higher pre-hospitalization National Health System (NHS) score (Duca et al. in Emerg Med Pract 22:1-2, 2020) (OR 1.27; 95% CI 1.05-1.6; p = 0.029) and more severe pulmonary disease expressed by the Brescia-COVID Respiratory Severity Scale (Duca et al. in Emerg Med Pract 22:1-2, 2020) (BCRSS > 1OR 4.73; 95% CI 1.53-14.63; p = 0.003) during the acute phase of the disease. This longitudinal study showed that the severity of COVID-19, indicated by BCRSS, and a complex score given by age and premorbid medical conditions, expressed by NHS, play a major role in modulating the long-term cognitive consequences of COVID-19 disease. These findings indicate that the association of age and premorbid factors might identify people at risk for long-term neurological consequences of COVID-19 disease, thus deserving longer and proper follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Cognitive deficits have been increasingly reported as possible long-term manifestations after SARS-CoV-2 infection.
AIMS
OBJECTIVE
In this study we aimed at evaluating the factors associated with cognitive deficits 6 months after hospitalization for Coronavirus Disease 2019 (COVID-19).
METHODS
METHODS
One hundred and six patients, discharged from a pneumology COVID-19 unit between March 1 and May 30 2020, accepted to be evaluated at 6 months according to an extensive neurological protocol, including the Montreal Cognitive Assessment (MoCA).
RESULTS
RESULTS
Abnormal MoCA scores at 6 months follow-up were associated with higher pre-hospitalization National Health System (NHS) score (Duca et al. in Emerg Med Pract 22:1-2, 2020) (OR 1.27; 95% CI 1.05-1.6; p = 0.029) and more severe pulmonary disease expressed by the Brescia-COVID Respiratory Severity Scale (Duca et al. in Emerg Med Pract 22:1-2, 2020) (BCRSS > 1OR 4.73; 95% CI 1.53-14.63; p = 0.003) during the acute phase of the disease.
DISCUSSION
CONCLUSIONS
This longitudinal study showed that the severity of COVID-19, indicated by BCRSS, and a complex score given by age and premorbid medical conditions, expressed by NHS, play a major role in modulating the long-term cognitive consequences of COVID-19 disease.
CONCLUSIONS
CONCLUSIONS
These findings indicate that the association of age and premorbid factors might identify people at risk for long-term neurological consequences of COVID-19 disease, thus deserving longer and proper follow-up.
Identifiants
pubmed: 35014002
doi: 10.1007/s40520-021-02042-3
pii: 10.1007/s40520-021-02042-3
pmc: PMC8747881
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-260Investigateurs
Ilenia Libri
(I)
Marcello Giunta
(M)
Matteo Cortinovis
(M)
Martina Locatelli
(M)
Barbara Risi
(B)
Francesca Schiano di Cola
(FS)
Nicola Zoppi
(N)
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Neurol Sci. 2015 Apr;36(4):585-91
pubmed: 25380622
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Am Geriatr Soc. 2021 Oct;69(10):2778-2780
pubmed: 34019707
J Neurol. 2020 Aug;267(8):2179-2184
pubmed: 32458193
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Nat Rev Neurol. 2020 Nov;16(11):636-644
pubmed: 32839585
JAMA. 2021 Apr 20;325(15):1525-1534
pubmed: 33729425
Neurology. 2020 Aug 18;95(7):e910-e920
pubmed: 32444493
J Am Geriatr Soc. 1995 Feb;43(2):130-7
pubmed: 7836636
Autoimmun Rev. 2020 Jul;19(7):102556
pubmed: 32361194
Emerg Med Pract. 2020 Apr 16;22(5 Suppl):CD1-CD2
pubmed: 32297727
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375